Brief: AB Science Announces Results From Masitinib Study Ab12003 In Prostate Cancer
13/09/2021 17:12
Sept 13 (Reuters) - AB Science SA ABS.PA :
* AB SCIENCE ANNOUNCED TODAY THAT RESULTS FROM MASITINIB
STUDY
AB12003 IN PROSTATE CANCER HAVE BEEN PRESENTED AT THE 2021
AMERICAN UROLOGICAL ASSOCIATION
* MASITINIB IS POSITIONED IN COMBINATION WITH DOCETAXEL AS A
FIRST-LINE TREATMENT OF METASTATIC CASTRATE REFRACTORY PROSTATE
CANCER (MCRPC) ELIGIBLE TO CHEMOTHERAPY
* THERE IS CURRENTLY NO DRUG REGISTERED FOR USE IN
COMBINATION
WITH STANDARD TREATMENT OF DOCETAXEL
Source text for Eikon: ID:nGNE9qL0WH
Further company coverage: ABS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on AB Science SA
See all newsBrief: AB Science Temporarily Halts Europe Clinical Trials Ahead Of Strategic Reorganization
Brief: AB Science Says FDA Granted Status Of Minor Use In Major Species For Masivet
Brief: AB Science Says Co Received Japanese Patent Protection To Use Masitinib In Progressive MS Until 2041
Brief: AB Science Phase 1 AML Study Of AB8939 Shows 100% Partial Response Rate
Brief: AB Science Receives Notice Of Allowance For European Patent Covering Masitinib Until 2040 In Treatment Of Sickle Cell Disease